Mathias Frederiksen

Mathias Frederiksen is a seasoned expert in the biotechnology and pharmaceutical sectors, currently serving as Principal at Novartis Venture Fund since February 2022, where responsibilities include discovering and nurturing biotech start-ups from seed to IPO. In addition, Mathias holds multiple board observer roles and directorships at various companies, including Exsilio Therapeutics and FundaMental Pharma, focusing on breakthrough therapies in neurodegeneration. Prior experience at Novartis Institutes for BioMedical Research involved significant leadership roles in chromatin chemical biology and neuroscience, culminating in the development of novel therapeutic agents. Mathias's academic credentials include a Postdoctoral Research Fellowship at Stanford University and a PhD in Synthetic Organic Chemistry from Imperial College London.